Strides Pharma Science’s $24 Million Acquisition of Endo’s US Manufacturing Facility

Haynes and Boone represented Strides Pharma Science Limited in the transaction.

Strides Pharma Science Limited announced that its wholly owned subsidiaries have entered into definitive agreements with subsidiaries of Endo International to acquire its manufacturing facility in New York and various Abbreviated New Drug Applications (ANDAs).

The acquisition is expected to close this year and Strides will further bolster its U.S. presence through acquisition of a multi-dosage facility in the U.S. and a basket of ANDAs across multiple therapeutic segments. The cumulative addressable market for the acquired portfolio is $4.7 billion.

Headquartered in India, Strides Pharma Science Limited is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules. 

The Haynes and Boone deal team was led by Simin Sun (Picture) and Jeff Wolfson, and included Partner Greg Kramer and Associates Reem Abdelrazik and Maseo Brown. Additional counsel was provided by an interdisciplinary Haynes Boone team, including: Raquel Alvarenga; Scott Thompson; Lucy Hong; Mordechai Sutton; Jack Turano; Suzie Trigg; Tony Subketkaew; Jeff Civins; Randall Colson; Ed Lebow; Matt Deffebach and Jennifer Kreick.

Involved fees earner: Reem Abdelrazik – Haynes and Boone; Raquel Alvarenga – Haynes and Boone; Maseo Brown – Haynes and Boone; Jeff Civins – Haynes and Boone; Randall Colson – Haynes and Boone; Matthew Thomas Deffebach – Haynes and Boone; Lucy Hong – Haynes and Boone; Greg Kramer – Haynes and Boone; Jennifer Kreick – Haynes and Boone; Edward Lebow – Haynes and Boone; Suzanne Trigg – Haynes and Boone; Tony Subketkaew – Haynes and Boone; Simin Sun – Haynes and Boone; Mordechai Sutton – Haynes and Boone; Scott Thompson – Haynes and Boone; Jack Turano – Haynes and Boone; Jeffrey Wolfson – Haynes and Boone;

Law Firms: Haynes and Boone;

Clients: Strides Pharma Science Limited;

Author: Martina Bellini